Gastro-esophageal reflux disease (GERD) has become prevalent in the modern lifestyle of people. GERD is a chronic digestive disorder, which is caused by the backflow of gastric contents into the esophagus, due to weakened lower esophageal sphincter (LES). One of the primary symptoms of GERD is heartburn, which occurs to 7% U.S. population on a daily basis. GERD has spread over the globe rapidly over the past decade and its prevalence is account to be 15-25%. GERD drastically affects the quality of life and may develop into esophageal cancer. There are several treatments available in the market including lifestyle modifications, medication, devices or endoscopic procedures & surgery. The death of treatment option is what drives the GERD market.
Most of the prevalent drugs have gone off patent, thus, paving the way for generics and over the counter (OTC) products in the market. But, due to low safety, efficacy & poor reimbursement of devices & procedures, these are not popular with the doctors and patients alike. Low acceptability along with the lack of new regulatory approved medication are major drawbacks in the growth of global GERD market.
The GERD drug market is booming with generics and OTC products, and by drug class, the market can be classified into antacids, proton pump inhibitors (PPI), histamine-2 receptor blockers (H2RA), prokinetics and, complementary and alternative medicines. The larger availability of anatacid over the counter and its instant relief properties make it the largest shareholder of the market. Antacid is followed by PPIs, which are the first line treatment in moderate to severe GERD.
The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023. This low growth is due to the related side-effects of drugs on prolonged use and higher number of patients who fail to respond to the medication. Thus, these factors along with the availability of new technology will help in the growth of device market in the future.
The global GERD market is dominated by drugs as of now as they are the first line treatment for the early & mild cases of GERD. Among the drugs, Proton Pump inhibitors currently has the largest share of 80%, which is expected to be 75% by 2023. Whereas, the device segment is growing at a CAGR of 15.3% from 2017 to 2023. The devices in the market can be categorized into invasive and non-invasive. MUSE, LINX reflux device, Stretta & GERD-X are some of the devices available in the market.
Invasive procedures in devices market include LINX management system and MUSE, while the non-invasive include EsophyX, Endostim, Stretta, Durasphere, and GERD-X. The market also includes diagnostic devices such as Bravo reflux management system & Digitrapper. The key players in the device market are Endogastric Solutions, Medigus Ltd., Medtronic Plc, Carbon Medical technologies, Johnson & Johnson etc.
BIS Healthcare has conducted an extensive market research on ‘Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market – Analysis and Forecast (2017-2023)’. The market intelligence report aims to provide an in-depth analysis of the key development strategies, marketing strategies and market trend dynamics which includes drivers, restraints and opportunities prevailing in the industry.
For further queries, please write to us at [email protected] or call us at: +1 650 228 0182.